FORM PTO-1390 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (MODIFIED) X16357 U.S. APPLICATION NO. (if known, see 37 C.F.R. 1.5) TRANSMITTAL LETTER TO THE UNITED STATES 10/568136 DESIGNATED/ELECTED OFFICE (DO/EO/US) **CONCERNING A FILING UNDER 35 U.S.C. 371** INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING PRIORITY DATE CLAIMED DATE 30 July 2004 (30.07.2004) PCT/US2004/022299 11 August 2003 (11.08.2003) TITLE OF INVENTION: 6-(2,2,2-TRIFLUOROETHYLAMINO)-7-CHLORO-2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINE AS A 5-HT2C RECEPTOR AGONIST APPLICANT(S) FOR DO/EO/US: Christopher Stanley Galka, and Michael John Rodriguez Applicant herewith submits to the U.S. Designated/Elected Office (DO/EO/US) the following items and other information: This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). The US has been elected (Article 31). A copy of the International Application as filed (35 U.S.C. 371(c)(2)) is transmitted herewith (required only if not transmitted by the International Bureau). b. has been transmitted by the International Bureau. is not required, as the application was filed in the United States Receiving Office (RO/US). c. A translation of the International Application into English (35 U.S.C. 371(c)(2)). 7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) are transmitted herewith (required only if not transmitted by the International Bureau). a. b. have been transmitted by the International Bureau. c. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made and will not be made. A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). X 10. A declaration of the inventors 35 U.S.C. 371(c)(4) was provided in the PCT Request Form. 11. A copy of the International Preliminary Examination Report (IPER), including any annexes, and, if not in English, an English language translation of the annexes to the IPER under PCT Article 36 (35 U.S.C. 371(c)(5)). An Information Disclosure Statement under 37 CFR 1.97 and 1.98. | X | Search Report/Written Opinion (ISA/EP) An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.

1.

2.

3.

4.

5.

6.

8.

Items 12. to 18. below concern document(s) or information included: 12. 13. 14. Assignment has been recorded at reel ______, frame _ 15. A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment. 16. A Sequence Listing, 1.821 Statement, and diskette. 17. A change of power of attorney with attachment. 18. Other items or information:

Please amend the first page of the specification by inserting the following cross-reference after the title: "This is the national phase application, under 35 USC 371, for PCT/US2004/022299, filed 30 July 2004 (30.07.2004), which, claims the benefit, under 35 USC 119(e), of US provisional application 60/494,208, filed 11 August 2003 (11.08.2003)."

IAP20 Ros'd PCT/PTO 09 FEB 2006

U.S. APPLICATION NO. 37 known, see 37 C.F.R. 1.51 INTERNATIONAL APPLICATION NO. 27 PCT/US2004/022299					O. ATTORNEY'S DOCKET NUMBER X16357			
19.	· ·					CALCULATIONS PTO USE ONLY		
(a)				***		300.00		
(a)	Basic national fee (37 CFR 1.492(a))\$300.00					300.00		
(b)	Examination fee (37 CFR 1.492(c))							
	If the written opinion prepared by ISA/US or the international preliminary							
	examination report prepared by IPEA/US indicates all claims satisfy					200.00		
	provisions of PCT Article 33(1)-(4)							
			1					
(c)	Search fee (37 CFR 1.492(b))							
	If the written opinion of the ISA/US or the International preliminary examination report prepared by IPEA/US indicates all claims satisfy							
	provisions of PCT Article 33(1)-(4)\$0					400.00		
	Search fee (37 CFR 1.445(a)(2)) has been paid on the international							
	application to the USPTO as an International Searching Authority\$100					:		
	International Search Report prepared by an ISA other than the US and provided to the Office or previously communicated to the US by the IB\$400							
	All other situations							
	All other situations	S		·	<u>_</u>	000.00		
$\frac{\text{TOTAL AMOUNT (a + b + c)}}{\text{Surcharge of $130.00 for furnishing the oath or declaration later than 30 months}}$					\$	900.00	-	
	e earliest claimed	priority date (37 CFR	1.492(e)).		J.			
Total c	CLAIMS	NUMBER FILED 10-20=	NUMBER EXTRA 0	RATE X \$50.00	<u></u>	0.00		
Independent claims		1-3=		X \$200.00	1 *	0.00		
MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$360.00					<u> </u>	0.00		
TOTAL OF ABOVE CALCULATIONS =					\$	0.00		
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity Statement					\$			
must also be filed (Note 37 CFR 1.9, 1.27, 1.28). SUBTOTAL =					•	000.00		
Processing fee of \$130.00 for furnishing English translation later than 30 months					\$	900.00		
from the earliest claimed priority date (37 CFR 1.492(f)). +								
TOTAL NATIONAL FEE =						900.00		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31).					\$			
\$40.00 per property +					<u> </u>			
TOTAL FEES ENCLOSED =					\$	900.00	Φ.	
						Amount to be refunded	\$	
						charged	\$	
a. A check in the amount of \$ to cover the above fees is enclosed.							-11:	
b. X Please charge my Deposit Account No. 05-0840 in the amount of \$900.00 to cover the above fees. A duplicate copy of this sheet is enclosed.								
c. X The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any								
overpayment to Deposit Account No. 05-0840. A duplicate copy of this sheet is enclosed. NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive								
(37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.								
SEND ALL CORRESPONDENCE TO: ELI LILLY AND COMPANY B. Cary								
PATENT DIVISION P.O. BOX 6288			SICNATURE					
INDIA	INDIANAPOLIS, INDIANA 46206-6288							
Date 9, 2006						25885		
DECIS:	45,165	,	433-9829 TELEPHONE NUMBER			THE TRADERIAR		

IN THE UNITED STATES RECEIVING OFFICE (USRO)

Applicant(s): Christopher Stanley Galka, and Michael John Rodriguez

International Application No.: PCT/US2004/022299

Filed: 30 July 2004 (30.07.2004)

Invention: 6-(2,2,2-TRIFLUOROETHYLAMINO)-7-CHLORO-2,3,4,5-TETRAHYDRO-1H-

BENZO[d]AZEPINE AS A 5-HT2C RECEPTOR AGONIST

Lilly Reference:

X16357

Earliest Priority Date: 11 August 2003 (11.08.2003)

Certificate Under 37 C.F.R. § 1.10

Attention: DO/EO
Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir/Madam:

"Express Mail" mailing label number: <u>EV 393128654 US</u>

Date of Deposit: FGb.09, 2006

I hereby certify that the following attached paper or fee

Transmittal Letter to the United States Designated/Elected Office (US) concerning a filing under 35 U.S.C. 371 of the International Application identified above is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

(Typed or printed name of person mailing paper)

(Signature of person mailing paper or fee)